[go: up one dir, main page]

ES2657226T3 - Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo - Google Patents

Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo Download PDF

Info

Publication number
ES2657226T3
ES2657226T3 ES10811290.5T ES10811290T ES2657226T3 ES 2657226 T3 ES2657226 T3 ES 2657226T3 ES 10811290 T ES10811290 T ES 10811290T ES 2657226 T3 ES2657226 T3 ES 2657226T3
Authority
ES
Spain
Prior art keywords
antibody
seq
pharmaceutical composition
monoclonal antibody
vegf monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10811290.5T
Other languages
English (en)
Inventor
Pierre Li
Yaohuang Ke
Yongke Zhang
Weimin Zhu
Guoliang Yu
Fanxin Ma
Xin FAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Simcere Pharmaceutical Co Ltd
Apexigen Inc
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Apexigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd, Apexigen Inc filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2657226T3 publication Critical patent/ES2657226T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo monoclonal que se une específicamente a VEGF, caracterizado porque el dominio variable de su cadena pesada comprende secuencias de aminoácidos de CDR 1-3 que consisten respectivamente en la SEQ ID NO. 1, SEQ ID NO. 2 y SEQ ID NO. 3, y el dominio variable de su cadena ligera comprende secuencias de aminoácidos de CDR 1-3 que consisten respectivamente en SEQ ID NO. 4, SEQ ID NO. 5 y SEQ ID NO. 6.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10811290.5T 2009-08-28 2010-08-27 Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo Active ES2657226T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2009101715509A CN102002104A (zh) 2009-08-28 2009-08-28 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN200910171550 2009-08-28
PCT/CN2010/076420 WO2011023130A1 (zh) 2009-08-28 2010-08-27 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Publications (1)

Publication Number Publication Date
ES2657226T3 true ES2657226T3 (es) 2018-03-02

Family

ID=43627282

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10811290.5T Active ES2657226T3 (es) 2009-08-28 2010-08-27 Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo

Country Status (6)

Country Link
US (1) US8986692B2 (es)
EP (1) EP2471814B1 (es)
JP (1) JP5738294B2 (es)
CN (2) CN102002104A (es)
ES (1) ES2657226T3 (es)
WO (1) WO2011023130A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103992405B (zh) * 2008-03-26 2016-08-17 宜康公司 抗-vegf抗体
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN102875676B (zh) * 2011-07-13 2014-11-05 无锡天演生物技术有限公司 全人源抗人vegf单抗分子及其应用
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2833530T3 (es) 2015-01-06 2021-06-15 Zhuhai Essex Bio Pharmaceutical Co Ltd Anticuerpo anti-VEGF
EP3973977A1 (en) 2015-03-31 2022-03-30 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
ES2951260T3 (es) 2015-09-01 2023-10-19 Il Dong Pharma Composición para su uso en el tratamiento del cáncer o de una enfermedad relacionada con la angiogénesis que comprende una proteína de fusión de un péptido de penetración tumoral y un agente anti-VEGF
KR20180068982A (ko) * 2015-09-14 2018-06-22 갤럭시 바이오테크, 엘엘씨 혈관신생 인자에 대한 매우 강력한 모노클로날 항체
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR102293755B1 (ko) 2016-01-06 2021-08-24 오더-메이드 메디컬 리서치 인코포레이티드 고친화성 항vegf 항체
CN108779172B (zh) 2016-01-06 2022-02-08 定制药品研究株式会社 抑制vegf与nrp1结合的抗体
CN107537036A (zh) * 2016-06-27 2018-01-05 江苏泰康生物医药有限公司 一种抗人血管内皮生长因子单克隆抗体的药物制剂及其应用
CN110003328B (zh) * 2018-01-05 2022-04-19 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
KR20220071177A (ko) * 2019-07-19 2022-05-31 사이노셀테크 엘티디. 인간화 항-vegf 단클론 항체
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022171109A1 (zh) * 2021-02-10 2022-08-18 上海济煜医药科技有限公司 抗vegf抗体及其用途
CN115850470B (zh) * 2022-12-12 2023-07-07 三门峡市眼科医院 Vegf抗体及其应用
CN116003619B (zh) * 2022-12-12 2023-08-04 三门峡市眼科医院 人源化抗Ang-2和VEGF双功能抗体及其医药用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
MXPA01010891A (es) * 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
CN1187373C (zh) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
JP2005535341A (ja) 2002-08-15 2005-11-24 エピトミスク インコーポレーティッド ヒト化ウサギ抗体
US20040067496A1 (en) 2002-10-07 2004-04-08 Robert Pytela System for production and screening of monoclonal antibodies
US8071322B2 (en) 2002-11-12 2011-12-06 Epitomics, Inc. Method for identifying differentially expressed proteins
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
WO2005007671A2 (en) 2003-04-29 2005-01-27 Epitomics, Inc. Compositions and methods for treating sars
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US20050287118A1 (en) 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) 2003-11-26 2005-12-15 Epitomics, Inc. High-throughput method of DNA immunogen preparation and immunization
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
CN101148474B (zh) * 2006-09-21 2014-06-11 上海杰隆生物工程股份有限公司 人源人血管内皮生长因子单克隆抗体及其制备方法
CA2666974A1 (en) * 2006-10-20 2008-11-06 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN101868477A (zh) 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
CN103992405B (zh) 2008-03-26 2016-08-17 宜康公司 抗-vegf抗体
US9365644B2 (en) 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
CN101487005A (zh) 2008-09-04 2009-07-22 林植华 人血管内皮生长因子单克隆抗体的基因及其应用
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
NZ607510A (en) 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
EP2702078B1 (en) 2011-04-29 2018-11-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US9057728B2 (en) 2011-07-12 2015-06-16 Epitomics, Inc. FACS-based method for obtaining an antibody sequence
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法

Also Published As

Publication number Publication date
JP5738294B2 (ja) 2015-06-24
CN102448987B (zh) 2014-06-04
EP2471814A1 (en) 2012-07-04
CN102448987A (zh) 2012-05-09
US8986692B2 (en) 2015-03-24
EP2471814B1 (en) 2018-01-03
WO2011023130A1 (zh) 2011-03-03
EP2471814A4 (en) 2013-04-03
CN102002104A (zh) 2011-04-06
US20120231011A1 (en) 2012-09-13
JP2013502445A (ja) 2013-01-24

Similar Documents

Publication Publication Date Title
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
ES2500066T3 (es) Anticuerpos frente a ferroportina y métodos de uso
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
ES2523740T3 (es) Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
ES2689080T3 (es) Anticuerpos que se unen a TL1A y sus usos
PE20171512A1 (es) Anticuerpos anti-fap
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
ES2684475T3 (es) Proteínas que se unen a beta amiloide
PE20121129A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
ES2664972T3 (es) Moléculas de unión anti-Psl de Pseudomonas y usos de las mismas
AR076018A1 (es) Anticuerpos multiespecificos especialmente biespecificos
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201790757A1 (ru) Связывающие антиген cd27l белки
AR083747A1 (es) Anticuerpos anti-il-23
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
AR069775A1 (es) Anticuerpos bivalentes biespecificos
CY1115030T1 (el) Διειδικα αντι-vegf/αντι-ang-2 αντισωματα
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN